Clarkston Shares Guest Column on the GLP-1 Production Process
May 5, 2026 | Clarkston Consulting’s Brandon Miller and Natalie Pollock recently shared a guest column with Bioprocess Online on the GLP-1 production process. Read an excerpt below and the full article here.
Gaining An Edge In GLP-1 Production
“GLP-1s are on track to become the biggest drug class in history, with annual sales projected to surpass $100 billion over the next five years.1 As of 2025, roughly 10 million Americans2 are on GLP-1s, for both treatment of type 2 diabetes and weight loss, and that number is expected to reach 25 million by 2030. This is especially significant because the pharmaceutical industry is currently shifting gears. The shortage-driven production of the past few years is giving way to a long-term operation model. Since GLP-1s are increasingly used as chronic therapies,3 this long-term model must support continuous production rather than episodic scaling to help meet this need. This change requires manufacturers to take a new approach to how they scale production.”
Also read on: